STATUTORY INSTRUMENTS

2019 No. 775

The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019

PART 3

Amendment of Part 3 (manufacture and distribution of medicinal products and active substances)

Amendment of Schedule 5 (review upon oral representations)

22.—(1) Schedule 5 [M1] is amended as follows.

(2) In paragraph 1(2)(e), 3(11)(b) and 5(2)(d) after—

(a) "UK marketing authorisation," in each place it appears, insert " parallel import licence, "; and

(b) "an authorisation," or "the authorisation," in each place it appears, insert " licence, ".

(3) In paragraph 3 omit sub-paragraph (11)(b)(iii).

(4) In paragraph 5 omit sub-paragraph (2)(c).

Commencement Information

I1 Reg. 22 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, **Sch. 5 para. 1(1)**), see reg. 1

Marginal Citations

M1 Schedule 5 was amended by S.I. 2013/1855.

Changes to legislation:
There are currently no known outstanding effects for the The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019, Section 22.